Results 61 to 70 of about 6,049 (169)

Chemical structures of febuxostat, ursolic acid and other xanthine oxidase inhibitors; allopurinol and febuxostat.

, 2018
Chemical structures of febuxostat, ursolic acid and other xanthine oxidase inhibitors; allopurinol and febuxostat.
Eman Abu-Gharbieh (3933140), Yasser Bustanji (2412991), Ihab M. Almasri (5638808), Naglaa G. Shehab (5638805)   +3 more
core   +1 more source

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age

BMC Geriatrics, 2012
Background The incidence of gout rises with increasing age. Management of elderly (≥65 years) gout patients can be challenging due to high rates of comorbidities, such as renal impairment and cardiovascular disease, and concomitant medication use ...
Jackson Robert L, Hunt Barbara, MacDonald Patricia A   +2 more
doaj   +1 more source

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato, Sara Salvagno, Chiara Colato, Paolo Gisondi, Giampiero Girolomoni   +4 more
wiley   +1 more source

Clinical pharmacokinetics and pharmacodynamics of febuxostat

, 2017
Febuxostat is a xanthine oxidoreductase inhibitor that has been developed to treat chronic gout. In healthy subjects, the pharmacokinetic parameters of febuxostat after multiple oral dose administration include an oral availability of about 85 %, an ...
Williams, Kenneth M., Pile, Kevin (R17082), Kamel, Bishoy S., Day, Richard O., Graham, Garry G.   +4 more
core   +1 more source

Alopurinol vs Febuxostat: Revisión bibliográfica [PDF]

, 2020
En el tratamiento de la hiperuricemia se utilizan dos fármacos principalmente, ambos inhibidores de la enzima xantina oxidasa, el alopurinol y el febuxostat.
Alvite Geraldes, Beatriz
core  

An integrated population pharmacokinetic model of febuxostat in pediatric patients with hyperuricemia including gout and adult population of healthy subjects and patients with renal dysfunction

Pharmacology Research & Perspectives
The study objective was to validate febuxostat dosage and administration in pediatric patients with hyperuricemia including gout, using an integrated population pharmacokinetic (PopPK) analysis in the Japanese population.
Ryutaro Iwama, Kimie Nishida, Daisuke Ishii, Takeshi Iijima   +3 more
doaj   +1 more source

Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study

Arthritis Research & Therapy, 2019
Background For patients with recurrent flares of gout, tophi, urate crystal arthropathy, and renal stones, urate-lowering therapies (ULTs, including allopurinol and febuxostat) are the first-line treatment.
Amayelle Rey, Benjamin Batteux, Solène M. Laville, Justine Marienne, Kamel Masmoudi, Valérie Gras-Champel, Sophie Liabeuf   +6 more
doaj   +1 more source

Multisystem Complications in Non‐Transfusion‐Dependent β‐Thalassemia Intermedia: A Case Highlighting the Need for Early Intervention

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT This case highlights that severe complications of non‐transfusion‐dependent β‐thalassemia may be preventable with appropriate monitoring and timely intervention; however, once established, multisystem complications can be challenging to treat.
Oldooz Aloosh, Seyedeh Esmat Hosseini, Mohammad Karimi   +2 more
wiley   +1 more source

Febuxostat and other drugs labeled for cardiovascular risk regulate similar signaling pathways.

, 2023
A) Structures of febuxostat, oxypurinol, topiroxostat, and febuxostat-1. B) The total number of pathways regulated by drugs with known cardiovascular risk that are also regulated by febuxostat (FBX), febuxostat-1 (FBX-1), topiroxostat (TPS), oxypurinol ...
Justin Taylor (338383), Brian D. LaMoreaux (16955386), Ryan E. Feaver (16955371), Banumathi K. Cole (16955377), Brian A. Johns (1833643), Andrew C. Nyborg (3597386), Robert A. Figler (10639022), Steve Hoang (16955380), Brad R. Henke (1453429), Lin Zhao (92451), M. Scott Bowers (16955374), Brian R. Wamhoff (199470), Mark J. Lawson (16955383)   +12 more
core   +1 more source

Severe Hypouricemia Impairs Endothelium‐Dependent Vasodilatation and Reduces Blood Pressure in Healthy Young Men: A Randomized, Placebo‐Controlled, and Crossover Study

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Uric acid (UA) is a plasmatic antioxidant that has possible effects on blood pressure. The effects of UA on endothelial function are unclear. We hypothesize that endothelial function is not impaired unless significant UA depletion is achieved ...
Benjamin De Becker, Catherine Coremans, Martin Chaumont, Cédric Delporte, Pierre Van Antwerpen, Thierry Franck, Alexandre Rousseau, Karim Zouaoui Boudjeltia, Pierre Cullus, Philippe van de Borne   +9 more
doaj   +1 more source